Plunkett Research Online: NuCana

NUCANA (NCNA:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

NuCana PLC is a biopharmaceutical company focused on improving treatment outcome for cancer patients by ProTide technology. Utilising the proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations.....



NuCana
Ticker: NCNA
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 44 1313571111
Fax:
Address: 3 Lochside Way
Edinburgh, EH12 9DT United Kingdom

Map
Types Of Business
Industry Ranks

Industry NAICS code:


Ranks not available
Contacts Description

NuCana PLC is a biopharmaceutical company focused on improving treatment outcome for cancer patients by ProTide technology. Utilising the proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations.....See More See More

Auditor: EY
Legal Advisor:
$USD, In whole numbers,
except marked * or %
2020 2019 2018 2017 2016 2015
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
Name Title Salary (US$) Bonus (US$)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: